Table 3

Clinicopathological parameters and responses to chemotherapy with urine TFF3 in gastric cancer patients
Parameters Cases (n) Urine TFF3 (ng/ml) P
Age
 ≤60 24 4.76 ± 0.72 0.089
 >60 22 8.33 ± 1.99
Gender
 Male 36 6.82 ± 1.30 0.529
 Female 10 5.20 ± 1.21
Site
 Fundus/Cardia 18 6.26 ± 1.23
 Gastric body 16 8.47 ± 2.54 0.087
 Antrum 12 4.10 ± 0.99
Degree of differentiation
 Well-moderately 27 6.35 ± 0.93 0.898
 Poorly 19 6.63 ± 2.20
Stage (I-III VS IV) 0.414
 I-II 9 4.15 ± 0.59
 III 5 6.40 ± 4.10
 IV 32 7.12 ± 1.36
Lymphatic metastasis
 N(-) 6 4.23 ± 0.79 0.743
 N(+) 9 7.12 ± 1.36
Distant metastasis
 M0 14 4.96 ± 1.44 0.346
 M1 32 7.12 ± 1.36
Responses to chemotherapy
 PR 6
  Befor-chemo 8.53 ± 1.93 0.189
  After-chemo 5.63 ± 0.72
 SD 9
  Befor-chemo 5.93 ± 0.94 0.76
  After-chemo 6.44 ± 1.35
 PD 9
  Befor-chemo 6.02 ± 1.68 0.053
  After-chemo 23.05 ± 7.44

Xiao et al.

Xiao et al. BMC Clinical Pathology 2014 14:26   doi:10.1186/1472-6890-14-26

Open Data